Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor
{{output}}
Background CLR457 is an orally bioavailable pan-phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) inhibitor. Methods CLR457 anti-tumor activity and pharmacokinetics (PK) were characterized by in vitro biochemical assays and in vivo tumor xenografts. A firs... ...
